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Abstract
Mutations in mitochondrial complex II (MCII; succinate dehydrogenase, Sdh) genes cause familiar pheochromocytoma/
paraganglioma tumors. Several mechanisms have been proposed to account for Sdh-mutation-induced tumorigenesis, the
most accepted of which is based on the constitutive expression of the hypoxia-inducible factor 1a (Hif1a) at normal oxygen
tension, a theory referred to as ‘‘pseudo-hypoxic drive’’. Other molecular processes, such as oxidative stress, apoptosis, or
chromatin remodeling have been also proposed to play a causative role. Nevertheless, the actual contribution of each of
these mechanisms has not been definitively established. Moreover, the biological factors that determine the tissue-
specificity of these tumors have not been identified. In this work, we made use of the inducible SDHD-ESR mouse, a
conditional mutant in the SdhD gene, which encodes the small subunit of MCII, and that acts as a tumor suppressor gene in
humans. The analysis of the Hif1a pathway in SDHD-ESR tissues and in two newly derived cell lines after complete SdhD loss
-a requirement for hereditary paraganglioma type-1 tumor formation in humans- partially recapitulated the ‘‘pseudo-
hypoxic’’ response and rendered inconsistent results. Therefore, we performed microarray analysis of adrenal medulla and
kidney in order to identify other early gene expression changes elicited by SdhD deletion. Our results revealed that each
mutant tissue displayed different variations in their gene expression profiles affecting to different biological processes.
However, we found that the Cdkn1a gene was up-regulated in both tissues. This gene encodes the cyclin-dependent kinase
inhibitor p21WAF1/Cip1, a factor implicated in cell cycle, senescence, and cancer. The two SDHD-ESR cell lines also showed
accumulation of this protein. This new and unprecedented evidence for a link between SdhD dysfunction and p21WAF1/Cip1
will open new avenues for the study of the mechanisms that cause tumors in Sdh mutants. Finally, we discuss the actual role
of Hif1a in tumorigenesis.
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Introduction
Germ-line mutations in the mitochondrial succinate dehydro-
genase (Sdh) enzyme -also referred to as mitochondrial complex II
(MCII)- or in its accessory units cause familial hereditary
pheochromocytoma and paraganglioma [1,2]. These are highly
vascularized, mostly benign tumors that occur mainly in the
adrenal gland and the carotid body. The MCII is composed of
four nuclear-encoded subunits (Sdh-A, B, C and D) that couple the
oxidation of succinate to fumarate in the Krebs cycle to the
mitochondrial electron transport chain. The first gene found to be
responsible for these types of tumors was SDHD [3]. Indeed, this
gene was the first tumor suppressor gene identified as encoding a
mitochondrial protein. Mutations on subunits B, C, A, as well as
on the accessory protein SDHAF2, have subsequently also been
implicated in paraganglioma, pheochromocytoma, renal cell
carcinomas, and gastrointestinal tumors [2,4,5].
Several mechanisms have been proposed to account for the
tumorigenic role of MCII mutations. One of the most accepted
involves constitutive stabilization of the hypoxia inducible factor
Hif1a. Due to its capacity to increase oxygen availability in tissues,
as well as to activate anaerobic metabolism, Hif1a plays a
fundamental role in tumor growth [6–10]. In Sdh-deficient
cultured cells [11,12] and tumors [13], succinate has been
observed to accumulate in the cytosol. Succinate inhibits
oxygen-dependent prolyl-hydroxylases (PHDs), responsible for
targeting Hif1a to the von Hippel-Lindau (pVHL) ubiquitin-ligase
for proteasome degradation in the presence of normal oxygen
tension [14]. Hence, inhibition of PHDs could prevent Hif1a
degradation in normoxic conditions, a situation termed to as
‘‘pseudo-hypoxia’’, which would favor tumor formation and
progression [9,12,13]. A role for oxidative stress in mitochon-
dria-linked tumorigenesis has also been proposed. Thus, impair-
ment of electron transfer at MCII would lead to electron leakage
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and/or possibly to a biased accumulation of the semi-reduced
form of ubiquinone, which ultimately may contribute to
mitochondrial reactive oxygen species (ROS) generation [15,16].
Diffusion of ROS throughout the cell would eventually cause
nuclear DNA damage and higher transforming mutation rates
[15,17,18]. Additionally, free radicals generated under these
conditions could also contribute to the stabilization of HIF1a by
keeping the PHD cofactors, iron and a-ketoglutarate, in reduced
form [14,19,20]. Another possibility is that accumulated succinate
might inhibit other components of the a-ketoglutarate-dependent
dioxygenase family such as histone demethylases, which might
thereafter alter the expression of oncogenes and tumor suppressor
genes [21]. Finally, inhibition of the normal pro-apoptotic activity
of PHD-3 by succinate during development has been suggested to
contribute to the pathogenesis of pheochromocytoma [22,23].
Despite these lines of evidence, mostly obtained from cell
culture studies, the precise molecular effects of MCII dysfunction
in vivo remain essentially unknown. This is largely due to the lack
of animal models that recapitulate defective Sdh-induced tumor-
igenesis. Homozygous knock-out mice for SdhB and SdhD are lethal
at embryonic stages, and the heterozygotes do not present tumors
or any other obvious pathology [24–26]. Conditional and tissue-
specific SdhD mutant strains generated by our group also failed to
show an increased predisposition to tumor occurrence [27]. These
data suggest that the mechanisms of tumor transformation could
differ between humans and rodents. In patients, tumor formation
in heterozygous, paternally inherited SDHD-mutation carriers
requires the loss of the maternal allele [3] in a phenomenon known
as loss of heterozygosity. This parent-of-origin effect suggests a
mechanism of genomic imprinting in the SDHD locus and/or
other regions of the same chromosome [28]. Loss of the entire
chromosome containing the gene has been observed in paragan-
glioma [29], which suggests that a "multiple-hit" process
implicating other loci in the same chromosome may be required
for tumor formation [30]. Given that chromosomal synteny is not
conserved between the two species, different chromosomal
arrangement could therefore account for the differences in tumor
appearance between SdhD-mutant humans and mice.
In the present study, we further characterize the SDHD-ESR
tamoxifen-inducible mouse model [27]. Based on the notion that
the aforementioned proposed molecular mechanisms of tumori-
genesis are triggered primarily by the complete loss of the SdhD
gene, we consider this mouse an ideal model in which to study the
early responses to the ‘‘second-hit’’ in paraganglioma, i.e., the loss
of the remaining SdhD functional allele. For this purpose, we first
analyzed the HIF1a pathway in SDHD-ESR mouse tissues as well
as in newly derived cell lines. Additionally, and given that none of
the hypothesis has been definitively established, we performed
large-scale gene expression analysis in SDHD-ESR adrenal
medulla and kidney tissue soon after SdhD deletion. Among other
changes, we found that there is a differential response between
these tissues, which might underlie the tissue-specificity of these
tumors. However, we consistently observed that the p21WAF1/Cip1
encoding gene is up-regulated in both organs. This protein is
implicated in many biological processes related to the cell cycle,
survival, and cancer. The same up-regulation was observed in the
cell lines. In light of the results obtained, we hypothesized that a
check-point mechanism is activated upon total SdhD loss, which
must be overcome by a subsequent third hit in order for the tumor
transformation to occur. We also discuss the actual role of the
Hif1a pathway in this process.
Materials and Methods
Mouse Strain, Husbandry and Treatment
The SDHD-ESR, with a SdhDflox/2 Cre-ERTM genotype,
tamoxifen-inducible mouse strain was generated as reported
previously [27]. Littermates with SdhDflox/+ and SdhDflox/2
genotypes lacking CRE recombinase are referred to as wild-type
homozygous (+/+) and heterozygous (+/2) mice, respectively, in
this work. When indicated, results from both genotypes were
pooled and assigned to a control group as no differences between
them was found for the phenotypes tested. Routine genotyping
was performed for the SdhD alleles by PCR with the following
primers: 59 AATTGTGCAGAAGTGAG-39, 59-GCTGCA-
TACGCTTGATC-39, 59-CATCAAGGCTCACAGTC-39. Mice
were housed under temperature-controlled conditions (22uC) in a
12 h light/dark cycle, and provided with food and water ad libitum.
Either high (100 mg/g for four days) or low (50 mg/g for two days)
doses of tamoxifen dissolved in corn oil were administered by daily
i.p. injections to 9–10 week-old animals.
Ethics Statement
All experiments were performed in accordance with institutional
guidelines approved by the ethics committee of the Virgen del
Rocio University Hospital. The protocol was approved by the
same committee according to the minute nu 02/2009.
DNA Analysis
Genomic DNA was extracted from nuclear fractions resulting
from mitochondrial preparations (see below) by overnight
incubation at 37u in 0.1 M Tris-HCl (pH 8.5), 5 mM EDTA,
0.2% SDS, 0.2 M NaCl, 100 mg/ml proteinase K. The relative
amount of the SdhDflox allele was estimated by quantitative PCR
with the following primers: 59-CTATGTAGGAGTCTGCAGC-
CAAGCT-39, 59-ACTCAAGGTCAGCCTCACCTACCTAT-
39, and normalized to the PCR product of the GusB gene.
Mitochondrial Isolation and Enzymatic Complex Activities
Isolation of mitochondria from mouse kidney was performed as
reported [25]. Mitochondrial complex I (MCI) and II activities
were determined according to ref. 25 with slight modifications.
Briefly, 30–50 mg of protein were assayed at 30uC. Samples were
diluted 1:4 in the assay reaction buffer (25 mM KH2PO4 pH 7.2,
5 mM MgCl2, 3 mM potassium cyanide, 2.5 mg/ml bovine
serum albumin) and liquid nitrogen frozen-thawed three times
before the assay. Rotenone-sensitive NADH-dehydrogenase
activity was measured as the decrease in absorbance at 340 nm,
referenced to 425 nm, due to oxidation of 130 mM NADH
(Roche) in the presence of 3.6 mM antimycin and 130 mM
ubiquinone-1 (Sigma). The absorbance was measured for 2 min
before and after the addition of 5 mM rotenone (Sigma) to the
reaction mixture. Differences between rates were considered when
determining activity due to MCI. The succinate-ubiquinone-
oxidoreductase activity of MCII was measured for a period of two
minutes as the decrease in the absorbance at 600 nm due to the
reduction of 50 mM 2,6-dichlorophenolindophenol (DCPIP) cou-
pled to the reduction of 130 mM ubiquinone-1. The reaction was
carried out in the presence of 3.6 mM antimycin, 5 mM rotenone
and 10 mM succinate.
Cell Lines
Cells were cultured in a humidified atmosphere of 5% CO2 at
37u in DMEM (Biowhittaker, BE12-614F) supplemented with
10% fetal bovine serum, MEM non-essential amino acids, 100 U/
ml penicillin, 1 mg/ml streptomycin and 0.29 mg/ml L-glutamine.
p21WAF1/Cip1 Overexpression in a SdhD Mouse Mutant
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Figure 1. Validation and tamoxifen dose-response characterization of the inducible SDHD-ESR mouse. A. Relative amount of SdhD
functional alleles (SdhD+ or SdhDflox) in kidney and liver as determined by quantitative PCR of genomic DNA prepared 3 weeks after the start of
injections of 100 mg/g, 4 times (high tx); or 50 mg/g, 2 times (low tx) tamoxifen. B. Succinate-ubiquinone oxidoreductase activity (SQR) of
mitochondrial complex II (MCII) and NADH-dehydrogenase (NDH) activity of mitochondrial complex I (MCI) in kidney and liver 3 weeks after the first
tamoxifen injection. C. Growth curves of 7-week-old mice after treatment with the same doses of tamoxifen. D. Survival curves of animals treated with
the low dose of tamoxifen. Control group includes homozygous (+/+) and heterozygous (+/2) individuals without CRE recombinase, as no
differences in the tested phenotypes were found between the two genotypes. Between 3 and 8 individuals per group were analyzed in each
experiment. *, P#0.05; **, P#0.01; ***, P#0.001.
doi:10.1371/journal.pone.0085528.g001
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Mouse embryonic fibroblasts (MEFs) were obtained from E13.5-
E15.5 embryos according to standard procedures. MEFs were
immortalized by electroporation with the plasmid pEF321-T
containing the SV40 large T antigen encoding gene (TAg), and
seeding of the cells at clonal density. Stably transformed clones
were subcultured, checked for the presence of TAg, and tested for
continuous growth ability. Baby mouse kidney (BMK) cells were
obtained from five-days-old mouse litters as reported [31]. For
immortalization, BMK cells were electroporated with the plasmids
pCMVE1A containing the viral oncogene E1A, and p53DD
containing a dominant negative mutant allele of p53 (kindly gifted
by Dr. Eileen White) according to a previously reported protocol
[32]. Four-hydroxy-tamoxifen (Sigma) was added to the medium
at 66 nM from a concentrated 2 mM stock in ethanol.
RNA Analysis
Tissues were dissected and stored frozen at 280u until
processing. Total RNA was prepared from mouse tissues and
cultured cells with TRIzolH reagent (Life Technologies), according
to the manufacturer’s directions for each type of sample. Total
RNA from the adrenal medulla, surgically separated from cortex,
was prepared using the RNeasyH microkit (Qiagen). Reverse
transcription of mRNA was performed with the Superscript II
reverse transcriptase kit (Life Technologies), and specific mRNA
molecules were amplified by quantitative PCR in the presence of
SYBR greenH (Life Technologies) with the following primers for
each gene: SdhD, 59-CCAGCACATTCACCTGTCA-39 and 59-
ATCAGCCCCAAGAGCAGAA-39; Vegf, 59-CGCAA-
GAAATCCCGGTTTAA-39 and 59-
CAAATGCTTTCTCCGCTCTGA-39; Glut1, 59-CCAGCTGG-
GAATCGTCGTT-39 and 59-CAAGTCTGCATTGCCCAT-
GAT-39; Phd3, 59-CAGACCGCAGGAATCCACAT-39 and 59-
CATCGAAGTACCAGACAGTCATAGC-39; Cdkn1a, 59-
TCCACAGCGATATCCAGACATT-39 and 59-CGGACAT-
CACCAGGATTGG-39. The Arbp housekeeping gene was used
for normalization with the primers 59-TCCAGGCTTTGGG-
CATCA-39 and 59-CTTTATCAGCTGCACATCACTCAGA-
39.
High-throughput Gene Expression Studies
Total RNA was prepared from the adrenal medulla and kidney
as above. Forty-five micrograms of RNA prepared from each
Figure 2. ‘‘Pseudo-hypoxic’’ response in SDHD-ESR mouse tissues. A. Succinate-ubiquinone oxidoreductase activity (SQR) in kidney 7 days
after the start of the tamoxifen treatment. B. Relative mRNA level of Vegf, Glut1, and Phd3 genes in kidney at 7 and 21 days after the start of the
tamoxifen treatment. n.d.: non-determined. C. Western blot of Hif1a with protein extracts from kidney after tamoxifen treatment. Protein extracts
from the pancreas of a b-cell-specific von Hippel-Lindau gene knock-out (VHL-KO) mouse and a wild-type littermate (VHL-wt) are loaded as controls.
n.a.: non-applicable. Between 3 and 8 individuals per group were analyzed in each experiment. *, P#0.05; ***, P#0.001.
doi:10.1371/journal.pone.0085528.g002
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Figure 3. ‘‘Pseudo-hypoxic’’ response in SDHD-ESR MEFs and BMK cells. A, B. Western blot of Hif1a and Glut1 in total protein extracts of
(A) mouse embryonic fibroblasts (MEFs) and (B) baby mouse kidney (BMK) cells obtained from SDHD-ESR mice and their homozygous SdhDflox/+ (+/+)
and heterozygous SdhDflox/2 (+/2) littermates and cultured in medium supplemented with 4-hydroxy-tamoxifen for 4 or 24 hours. C, D.
p21WAF1/Cip1 Overexpression in a SdhD Mouse Mutant
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kidney sample were further purified with the RNeasyH microkit
(Qiagen). For microarray analysis, 200 ng (kidney) or 45 ng
(adrenal medulla) of RNA were reverse-transcribed into cRNA
and labeled with the Two-Color Microarray Low Input Quick
Amp Labeling Kit (Agilent Technologies). Samples from 8
homozygous (+/+) individuals were pooled, labeled with cyanine
3-CTP (Cy3), and used as reference samples. Samples from 8
heterozygous (+/2) and 8 SDHD-ESR individuals were labeled
with cyanine 5-CTP (Cy5) and used as test samples. All the
individuals used were males. Labeled cRNA was mixed and
hybridized against the oligonucleotide microarray slides Mouse
GE 4644 k V2 (Agilent Technologies). The microarrays were
scanned in a GenePixH reader, with data acquired at wavelengths
of 635 nm and 532 nm for Cy3 and Cy5, respectively. Acquired
data were analyzed with the open-source Multi-Experiment
Viewer software [33]. Values are represented as the log Cy5/
Cy3 ratio of fluorescence intensities. the data generated in this
study have been deposited in NCBI’s Gene Expression Omnibus
and are accessible through GEO Series accession number
GSE52197 (http://www.ncbi.nlm.nih.gov/geo/query/acc.
cgi?acc=GSE52197). The functional analysis was generated
through the use of Ingenuity Pathways Analysis (IPA; Ingenuity
SystemsH, www.ingenuity.com).
Western Blot
For protein preparation, tissues and cells were homogenized in
ice-cold HEN buffer (5 mM EDTA, 250 mM NaCl, 50 mM
Hepes pH 7.3, 5 mM DTT) containing 1 mM Na3VO4, 0.2%
IGEPAL CA-630 (Sigma) and 1% protease inhibitor cocktail
(Sigma). Homogenized samples were centrifuged for 30 min. at
high speed in a microcentrifuge, after which protein containing
supernatant was collected. Protein concentration was determined
using a protein assay kit from Bio-Rad. From each sample, 50 mg
of protein was separated by electrophoresis on SDS–polyacryl-
amide gels and electroblotted onto PVDF membranes. Blots were
incubated in blocking solution (5% non-fat milk in PBS, 0.1%
Tween-20 [PBS-T]), followed by overnight incubation with the
following antibodies: anti-HIF1a (Cayman, CAY-1006421; dilu-
tion 1:500); anti-Glut1 (Millipore, 07-1401; dilution 1:800); anti-
p21WAF1/Cip1 (Santa Cruz Biotechnology Inc., sc397; dilution
1:200); and anti-b-actin (Abcam, ab6276; dilution 1:5000). The
membranes were then washed with PBS-T and incubated with
either a HRP conjugated goat anti-rabbit IgG antibody (Thermo,
31460; dilution 1:10000) or HRP conjugated sheep anti-mouse
IgG antibody (ECL, NA931V; dilution 1:10000). Antibody
detection was performed with an enhanced chemiluminescence
reaction (Clarity western ECL substrate; Bio-Rad).
Statistical Analysis
Data are presented as mean 6 standard error (SEM). Statistical
significance was assessed by ANOVA with appropriate post-hoc
analysis. For paired groups, either a Student’s t-test with a Levene
test for homogeneity of variances in the case of normal
distribution, or the nonparametric U-Mann Whitney test in the
case of non-normal distributions, was applied. PASW18 software
was used for statistical analysis. Statistical analysis of the
microarray data was performed with the Multi-Experiment
Viewer software [33] and the R programming language v3.2
(Vienna, Austria). False discovery rate (FDR) algorithm was used
to identify genes in the datasets corresponding to +/2 and
SDHD-ESR groups differentially expressed respect to the +/+
genotype. Functional analysis with IPA was performed according
to the tools provided in the software used.
Results
Validation and Dose-response Characterization of the
SDHD-ESR Mouse
The tamoxifen-inducible SDHD-ESR mutant mouse was
generated as previously reported [27]. In order to assess the
general CRE-mediated deletion of the SdhD gene, we analyzed the
relative presence of the SdhDflox allele by quantitative PCR of total
genomic DNA prepared from kidney and liver three weeks after
the first tamoxifen injection (Figure 1A). The relative amount of
functional SdhDflox allele in SDHD-ESR tissues decreased to about
16% and 54% in kidney and liver, respectively, with respect to the
heterozygous SdhDflox/2 without CRE (+/2 genotype). When a
lower dose of tamoxifen was administered, a lesser decrease was
observed (Figure 1A). The stronger effect of tamoxifen on kidney
versus liver as well as the dose dependency, were corroborated in
functional studies by determining the succinate-ubiquinone
oxidoreductase (SQR) activity of the MCII in the same tissues
[27] (Figure 1B). The SQR activity in SDHD-ESR kidney and
liver decreased to about 32% and 64% of the heterozygous level,
respectively, whereas the NADH-dehydrogenase activity in these
same tissue extracts was little or not significantly affected. This
tamoxifen dose-dependency was translated to the general pheno-
type of mutant SDHD-ESR individuals as these animals stopped
gaining weight after administration of the drug, and with the
higher dose, even lost weight after two weeks (Figure 1C). High-
dose tamoxifen-treated mutants were sacrificed before showing
evident signs of suffering. Low-dose tamoxifen-treated mutants,
although surviving longer than the high-dose treated animals, still
had a shorter average life-span (7 weeks) than their wild-type
littermates (Figure 1D). Since the treatment with the low dose of
tamoxifen casts doubt about the efficient deletion of SdhD in all the
tissues, the rest of experiments shown here were performed with
the high dose.
The ‘‘Pseudo-hypoxic Drive’’ is Partially Recapitulated in
SDHD-ESR Tissues
To address the possible activation of the ‘‘pseudo-hypoxic
drive’’ mechanism [11–13], the expression of several HIF1a target
genes was analyzed in wild-type (homozygous; +/+), heterozygous
(+/2) and SDHD-ESR mutant tissues. We present here data
obtained from kidney as this organ shows the most intense SdhD
deletion of those analyzed. To prevent possible secondary effects
due to the sustained lack of the gene in the animals three weeks
after the start of the of treatment, we included in our analysis
kidney samples obtained one week after the first tamoxifen
injection. At this time point, SQR activity had already decreased
considerably (Figure 2A). The messenger RNA levels of vascular
endothelial growth factor (Vegf), glucose transporter 1 (Glut1), and
prolylhydroxylase 3 (Phd3) genes were determined by RT-qPCR,
Quantification of relative Hif1a and Glut1 band intensities in (C) MEFs and (D) BMK cells normalized to b-actin signal. Results are the average 6 SEM
of three independent experiments. *, P#0.05; **, P#0.01; ***, P#0.001; for 0 hours, i.e. in the absence of 4-hydroxy-tamoxifen, versus 4 or 24 hours of
incubation in 4-hydroxy-tamoxifen. E, F. Messenger RNA levels of Vegf, Glut1, and Phd3 genes in (E) MEFs and (F) BMK cells cultured in the same
conditions. *, P#0.05; **, P#0.01; Two different immortalized clones were generated for each genotype and cell type giving the same results. Only
results from one of each are shown.
doi:10.1371/journal.pone.0085528.g003
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Figure 4. Microarray analysis. A. SdhD mRNA levels in heterozygous (+/2) and SDHD-ESR adrenal medulla and kidney relative to wild-type (+/+)
tissues 7 days after the start of the tamoxifen treatment, as obtained from the corresponding microarray feature (Gene Bank accession nu
NM_025848). *, P#0.05; ***, P#0.001. The number of samples is 8 per group. B. Supervised hierarchical clustering of adrenal medulla (AM) and
kidney samples based on genes that showed significant differences in their expression level. The heatmap and the hierarchical tree are shown for 8
samples, grouped in pairs, per genotype.
doi:10.1371/journal.pone.0085528.g004
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revealing a non-statistically significant trend towards an increase in
heterozygous animals compared with wild-type individuals
(Figure 2B). However, when the remaining functional copy of
SdhD was deleted, a significant induction of Vegf was observed in
the SDHD-ESR kidney only three weeks after the start of
injections, whereas for Glut1 and Phd3 their mRNA levels did not
significantly increase further (Figure 2B). Moreover, no signs of
Hif1a accumulation were observed, with this protein remaining
undetected in mutant tissues as assessed by western blot at both
time points (Figure 2C). As a control, protein extracts from a
tissue-specific knock-out mouse for pVHL [34] showed induced
expression of Hif1a. In addition, no increase was observed for any
of the same tested genes in liver and brain (data not shown).
Western blot of the same tissue extracts against the Hif2a antibody
also produced no signal (data not shown). Together, these data
suggest that activation of ‘‘pseudo-hypoxic drive’’ as a conse-
quence of MCII depletion does not take place in a general and
obvious manner in the analyzed mouse tissues.
The ‘‘pseudo-hypoxic drive’’ in SDHD-ESR-derived cell
lines differs from that in tissues. As the diffusion kinetics of
the drug throughout the mouse tissues could expand the SdhD
deletion on time, thus hampering the detection of transitory Hif1a
stabilization and the transcriptional activation of its target genes,
we decided to establish cell lines from the SDHD-ESR mouse in
which the accessibility of the cells to the drug is better controlled.
We newly derived and immortalized the commonly used mouse
embryonic fibroblasts (MEFs) cell type, as well as the epithelium-
derived baby mouse kidney (BMK) cells, which are more suitable
for the study of the biology of epithelial-derived tumors [31]. The
BMK cells have recently proved to be useful for identifying
synthetic lethal genes with the Krebs cycle enzyme fumarate
hydratase [35], which is closely related to Sdh. Loss of SdhD was
confirmed following addition of tamoxifen to the culture medium
in two independent immortalized clones per cell type (data not
shown). We tested the pseudo-hypoxia pathway in our immortal-
ized MEF and BMK cell lines after tamoxifen exposure. Whereas
in heterozygous lines no differences were found in either Hif1a or
Glut1 protein levels with respect to the wild type, the SDHD-ESR
mutant line underwent accumulation of both proteins, although
with different kinetics of induction (Figure 3A–D). When mRNA
levels were determined for some Hif1a-target genes, Phd3 and
Glut1 expression were found to be induced in the SDHD-ESR cell
line, whereas Vegf expression was not, or was even significantly
down-regulated (Figure 3E, F). These results, although indicative
of a ‘‘pseudo-hypoxic drive’’ effect on SdhD-null cell lines, contrast
strongly with the observations made in mouse tissues.
Microarray studies in two mouse tissues reveal
differential responses to SdhD deletion. With the aim of
identifying alternative molecular pathways altered upon SdhD
deletion, and to determine if some tissue-specific features could
condition the transcriptional response to MCII depletion, we
performed high-throughput gene expression analysis of kidney and
adrenal medulla tissue. The adrenal medulla was chosen because it
is one of the main pheochromocytoma/paraganglioma target
tissues. The kidney was chosen not only because of the more
intense effect on SdhD deletion exerted by tamoxifen, but also due
to the finding that renal cell carcinoma, although much less
frequently, is also associated with Sdh-mutations. To minimize
secondary effects on gene expression, we analyzed samples
obtained one week after the first tamoxifen injection. At this time
point, SdhD mRNA levels in both tissues had already decreased
considerably [27] (Figure 4A). It is worth to mention that at this
time-point no major histological abnormalities were detected for
any of the tissues analyzed. For large-scale gene expression analysis
we performed two-color microarray hybridization. Total RNA
from wild-type individuals was labeled with the fluorescent dye
Cy3 and used as the reference sample. Total RNA from either
heterozygous (+/2) or SDHD-ESR individuals was labeled with
the fluorescent dye Cy5 and used as the test samples. In this way,
the relative abundance of each transcript was monitored by the
ratio between the two fluorescence intensities in their correspond-
ing spot-features. Among the genes that were significantly affected
in tissues from SDHD-ESR animals (FDR#0.05) those showing
statistically significant differences in expression between +/2 and
SDHD-ESR groups (P#0.05) were identified and analyzed.
Remarkably, some genes that have previously been shown to
respond to hypoxia in a HIF1a-dependent manner were not
overexpressed in null SdhD deficient tissues (table 1). Supervised
hierarchical clustering of samples based on the significant genes
demonstrated different gene expression profile changes between
the adrenal medulla and kidney (Figure 4B). For functional
analysis, the entire datasets containing gene identifiers and their
corresponding expression values were uploaded into the Ingenuity
Pathway Analysis (IPA) application. A log ratio 60.2 cut-off was
set to identify genes whose expression was differentially regulated.
As an internal control we detected the aforementioned decreases
to about half of the SdhD mRNA level in the heterozygous (+/2)
tissues, and to 2% and 7% in the adrenal medulla and kidney,
respectively, in the SDHD-ESR mice (Figure 4A; table 2). As our
initial objective was to identify biological pathways exclusively
affected by complete loss of SdhD, functional analysis of their
respective datasets was performed focusing on SDHD-ESR
samples. Most of the significant high-level molecular and cellular
functions found to be affected differed greatly between the adrenal
medulla and kidney (Figure 5A). The highest scores were given to
the adrenal medulla dataset and were categorized in cellular
movement, maintenance, development, growth and proliferation
categories, as well as cell-to-cell signaling and interaction, among
others. On the other hand, functions found to be solely affected in
the kidney were energy production, cellular response to therapeu-
tics, amino acid metabolism, and DNA replication, recombination
and repair. When these functional categories were analyzed using
an algorithm that predicts the effect of gene expression changes on
specific functions, the significant results in adrenal medulla
samples (z-score $2, or # 22) predicted decreases in white blood
cell movement, viability, proliferation and production of antibody
(table 3), which is consistent with an inhibition of the inflammatory
Table 1. Expression levels of HIF1a-mediated hypoxia
responsive genes.
Adrenal medulla Kidney
+/2 SDHD-ESR +/2 SDHD-ESR
Glut1 20.09960.216 20.32360.304 20.17660.207 20.45560.276
HK2 0.72260.565 20.26260.449 20.06160.201 0.02160.323
LDHA 20.04260.517 20.04160.413 1.95960.813 1.48160.841
PDK1 20.31560.237 0.12660.127 20.04360.153 20.78560.153
Vegf 20.07660.192 20.13360.203 20.39160.175 20.62160.216
Date are expressed as the log ratio 6 SEM between either the homozygous
(+/2) or the inducible SDHD-ESR mutant and the wild type (+/+) expression
levels for each gene in each tissue as obtained from the microarray analysis.
Glut1: glucosyltransferase 1 (NM_172380), HK2: Hexokinase 2 (NM_013820),
LDHA: Lactate dehydrogenase A (NM_001136069), PDK1: Pyruvate
dehydrogenase kinase 1 (NM_172665), Vegf: Vascular endothelial growth factor
(NM_001025257).
doi:10.1371/journal.pone.0085528.t001
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response. In contrast, specific functions significantly predicted to
increase in the kidney were cell movement, survival, differentia-
tion, and death, as well as carbohydrate, lipid and amino acid
metabolism (table 4). Despite these differences, some few genes
were found to be affected in both tissues. They are ACOT1,
Camk2b, CDKN1A, ESR1, HSD11B1, LONRF3, MST1R,
Table 2. Most strongly up- and down-regulated genes in SDHD-ESR tissues.
Adrenal medulla
Log Ratioa ID Symbol Entrez Gene Name FDR
3.035 NM_025687 TEX12 testis expressed 12 0.043
2.541 NM_007956 ESR1 estrogen receptor 1 0.033
2.349 NM_001111099 CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) 0.006
2.018 NM_011356 FRZB frizzled-related protein 0.014
1.701 NM_170599 IGSF11 immunoglobulin superfamily, member 11 0.005
1.629 NM_011228 RAB33A RAB33A, member RAS oncogene family 0.002
1.595 NM_001001979 MEGF10 multiple EGF-like-domains 10 0.033
1.248 NM_023529 MS4A10 membrane-spanning 4-domains, subfamily A, member 10 0.006
1.062 NM_028733 PACSIN3 protein kinase C and casein kinase substrate in neurons 3 2.42E-7
1.040 NM_001081147 OXTR oxytocin receptor 2.25E-4
25.326 NM_025848 SDHD succinate dehydrogenase complex, subunit D 2.52E-5
22.129 NM_007988 FASN fatty acid synthase 2.77E-4
21.673 NM_001145164 Tgtp1/Tgtp2 T cell specific GTPase 1 4.78E-5
21,505 NM_010174 FABP3 fatty acid binding protein 3 0.022
21.458 NM_010501 IFIT3 interferon-induced protein with tetratricopeptide repeats 3 0.004
21.311 NM_013653 CCL5 chemokine (C-C motif) ligand 5 1.75E-4
21.186 NM_009930 COL3A1 collagen, type III, alpha 1 2.85E-5
21.134 NM_018738 Igtp interferon gamma induced GTPase 3.24E-5
21.062 NM_013585 PSMB9 proteasome (prosome, macropain) subunit, beta type, 9 1.78E-4
21.037 NM_007572 C1QA complement component 1, q subcomponent, A chain 1.50E-7
Kidney
Log Ratioa ID Symbol Entrez Gene Name FDR
2.931 NM_007956 ESR1 estrogen receptor 1 8.91E-4
2.623 NM_008239 FOXQ1 forkhead box Q1 6.26E-5
2.245 NM_080852 Slc7a12 solute carrier family 7, member 12 6.40E-4
2.163 NM_138595 GLDC glycine dehydrogenase (decarboxylating) 4.88E-5
2.066 NM_025687 TEX12 testis expressed 12 2.03E-6
1.964 NM_007669 CDKN1A cyclin-dependent kinase inhibitor 1A (p21, Cip1) 4.52E-4
1.915 NM_008256 HMGCS2 3-hydroxy-3-methylglutaryl-CoA synthase 2 2.69E-3
1.869 NM_010196 FGA fibrinogen alpha chain 0.015
1.855 NM_145368 Acnat1/Acnat2 acyl-coenzyme A amino acid N-acyltransferase 1 0.002
1.774 NM_016668 BHMT betaine-homocysteine S-methyltransferase 0.032
23.737 NM_025848 SDHD succinate dehydrogenase complex, subunit D 3.56E-6
22.479 NM_011315 Saa3 serum amyloid A 3 6.23E-4
22.380 AK143946 ACSM3 acyl-CoA synthetase medium-chain family member 3 7.98E-5
21.546 NM_001081688 TMPRSS9 transmembrane protease, serine 9 5.77E-6
21.306 NM_009127 SCD stearoyl-CoA desaturase (delta-9-desaturase) 5.93E-5
21.201 NM_146086 PDE6A phosphodiesterase 6A, cGMP-specific, rod, alpha 4.14E-4
21.007 NM_145360 IDI1 isopentenyl-diphosphate delta isomerase 1 1.12E-4
20.829 NM_009892 Chi3l3/Chi3l4 chitinase 3-like 3 6.23E-4
20.793 NM_181849 FGB fibrinogen beta chain 0.015
20.637 NR_002860 A130040M12Rik RIKEN cDNA A130040M12 gene 1.76E-4
a; Values .0 indicate up-regulated genes. Values ,0 indicate down-regulated genes. FDR: False discovery rate.
doi:10.1371/journal.pone.0085528.t002
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Figure 5. Functional analysis and validation of the microarray. A. Comparative functional analysis of datasets generated from adrenal
medulla (AM) and kidney samples from SDHD-ESR mice. The significance of each molecular and cellular function is indicated by –log of the p-value.
B. Quantitative RT-PCR of RNA samples used in the microarray study based on specific primers for amplification of the Cdkn1a mRNA.
doi:10.1371/journal.pone.0085528.g005
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PRODH2, SHANK3, STAT3, SMARCD3, and TEX12. Among
them, Cdkn1a was significantly up-regulated and showed a log
ratio of intensities $1 in both the adrenal medulla and kidney of
the SDHD-ESR mutant (table 2). This effect was validated by
quantitative RT-PCR (Figure 5B). The Cdkn1a gene encodes the
cyclin-dependent kinase inhibitor p21WAF1/Cip1, and is well known
to be implicated in many processes such as the cell cycle, cell
proliferation, senescence and cancer [36,37].
p21WAF1/Cip1 expression is induced in SDHD-ESR-
derived cell lines. To confirm the up-regulation of p21WAF1/
Cip1 in SdhD-deficient cells, we analyzed its expression in the MEF
and BMK cell lines described above. In both cell types, p21WAF/
Cip expression was strongly up-regulated in the mutant SDHD-
ESR cell lines 4 hours after tamoxifen-induced SdhD deletion, and
the amount of protein remained increased after 24 hours (Figure 6).
In contrast, there were no signs of accumulated protein in the
heterozygous cell lines at any time.
Discussion
In this study, we aimed to identify the molecular events
triggered after the second hit of the process of MCII mutation-
induced tumorigenesis by inducing loss of the second SdhD allele
in vivo. To achieve this, we made use of the conditional tamoxifen-
Table 3. Biological functions predicted to be affected in the SDHD-ESR adrenal medulla.
Functions
Annotation p-Value
Predicted
Activation
State
Activatio
z-score # Genes Genes
leukocyte
migration
2,95E-10 Decreased 22,618 41 ADORA3, ANGPTL2, CASP1, CD1D, CD48, CDKN1A, CRP, CTSC, CX3CR1, CXCL14, CXCL9,
CXCR3, CXCR5, CYSLTR1, DCN, FCER1G, FCGR2B, FUT4, HCK, HDC, HEBP1, IL1B, IL4R,
LDLR, LGALS3, LILRB3, MDK, MMP9, MPP1, MYO1F, NCKAP1L, PRKCD, RAC2, SELPLG,
SEMA4D, STAT3, SYK, TIRAP, TLR2, TYROBP, VIPR1.
cell viability
of leukocytes
7,94E-04 Decreased 22,617 11 EGF, FCER1G, IL1B, IL2RG, LGALS3, RAC2, SEMA4D, SHH, STAT3, SYK, TYROBP.
degranulation
of mast cells
7,86E-07 Decreased 22,574 11 ADORA3, DHCR7, FCER1G, FCGR2B, HCK, IL1B, IL4R, RAC2, SYK, TLR2, VAV1.
degranulation
of phagocytes
3,79E-08 Decreased 22,572 13 ADORA3, ANXA3, DHCR7, FCER1G, FCGR2B, HCK, IL1B, IL4R, MYO1F, RAC2, SYK,
TLR2, VAV1.
infiltration of
cells (leukocytes)
1,09E-05 Decreased 22,507 19 CASP1, CD48, CXCR5, DCN, FCER1G, FCGR2B, FUT4, HCK, IL1B, IL4R, LDLR, LGALS3,
MDK, MMP9, PRKCD, RAC2, SELPLG, STAT3, TLR2.
cell movement
of blood cells
(macrophages,
granulocytes,
antigen presenting
cells, leukocytes)
8,78E-11 Decreased 22,477 42 ADORA3, ANGPTL2, CASP1, CD1D, CD48, CDKN1A, CRP, CTSC, CX3CR1, CXCL14,
CXCL9, CXCR3, CXCR5, CYSLTR1, DCN, FCER1G, FCGR2B, FUT4, GJA1, HCK, HDC,
HEBP1, IL1B, IL4R, LDLR, LGALS3, LILRB3, MDK, MMP9, MPP1, MYO1F, NCKAP1L,
PRKCD, RAC2, SELPLG, SEMA4D, STAT3, SYK, TIRAP, TLR2, TYROBP, VIPR1
cell death
of immune
cells
1,33E-06 Decreased 22,458 27 ADORA3, C1QA, CASP1, CASP3, CD27, CD79B, CDKN1A, CRP, EGF, FCER1G,
FCGR2B, FLT3, IL1B, IL2RG, LDLR, LGALS3, PRKCD, RAC2, SEMA4D, SHH,
ST6GAL1, STAT3, SYK, TLR2, TNFAIP8L2, TYROBP, VAV1.
proliferation
of T lymphocytes
6,66E-06 Decreased 22,360 26 ARHGDIB, BATF, CASP3, CD1D, CD27, CD48, CD83, CDKN1A, CRP, EBI3, FCER1G,
FCGR2B, HLA-DRB1, IL1B, IL2RG, IL4R, MMP9, NCKAP1L, RAC2, SHH, STAT3, SYK,
TLR2, TRAF5, TYROBP, VAV1.
activation of
T lymphocytes
2,81E-03 Decreased 22,337 12 CD1D, CD48, CDKN1A, DCT, FCER1G, IL1B, IL2RG, LDLR, SEMA4D, STAT3, TLR2, VAV1.
phagocytosis
of cells
4,81E-04 Decreased 22,263 11 ANXA3, C1QA, CRP, FCER1G, FCGR2B, HCK, LGALS3, RAC2, SYK, TLR2, VAV1.
adhesion of
granulocytes
1,42E-03 Decreased 22,213 6 HCK, IL1B, LGALS3, MMP9, SELPLG, VAV1.
production
of superoxide
1,07E-04 Decreased 22,208 8 CXCL9, CYBA, GCH1, HCK, IL1B, RAC2, TLR2, TYROBP.
immune response
of antigen
presenting cells
1,60E-03 Decreased 22,160 8 CD1D, FCER1G, FCGR2B, HCK, LGALS3, MARCH1, SYK, TLR2.
migration of cells 1,11E-06 Decreased 22,157 53 ABI3, ADORA3, ANGPTL2, ANXA3, CASP1, CD1D, CD48, CDKN1A, COL3A1, CRP,
CSPG4, CTSC, CX3CR1, CXCL14, CXCL9, CXCR3, CXCR5, CYSLTR1, DCN, EGF, FCER1G,
FCGR2B, FUT4, GJA1, HCK, HDC, HEBP1, IL1B, IL4R, LDLR, LGAL S3, LILRB3, MDK,
MMP9, MPP1, MYO1F, NCKAP1L, PRKCD, RAC2, SELPLG, SEMA4D, SHH, SORT1, ST8SIA4,
STAT3, SYK, TGFB3, THRB, TIRAP, TLR2, TMSB10/TMSB4X, TYROBP, VIPR1.
quantity of IgM 1,83E-03 Decreased 22,157 8 BATF, CD83, CDKN1A, FCGR2B, IL2RG, LDLR, PRKCD, TRAF5.
production of antibody2,38E-08 Decreased 22,077 22 BATF, C1QA, CD1D, CD83, CDKN1A, CXCL9, FCER1G, FCGR2B, IL2RG, IL4R, LDLR,
LGALS3, MMP9, PRKCD, SEMA4D, TIRAP, TLR1, TLR2, TNFAIP8L2, TRAF5, TYROBP, VAV1.
phagocytosis of blood
cells
1,41E-04 Decreased 22,043 9 CRP, FCER1G, FCGR2B, HCK, LGALS3, RAC2, SYK, TLR2, VAV1.
doi:10.1371/journal.pone.0085528.t003
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inducible SDHD-ESR mouse mutant [27]. This model does not
seem to recapitulate the proposed ‘‘pseudo-hypoxic’’ response to
MC-II depletion [9,12,13] in a general and consistent manner.
Indeed, two newly derived and immortalized SDHD-ESR cell
lines showed a response to some extent incoherent with the results
obtained in animal tissues. Therefore, we aimed at identifying
other molecules potentially responding to the SdhD deletion. High-
throughput analysis of gene expression allowed us to identify the
Cdkn1a gene, which encodes the cyclin-dependent kinase inhibitor
p21WAF1/Cip1, as being up-regulated in two SdhD-deficient tissues.
We also evaluated whether or not p21WAF1/Cip1 was also affected
in the SDHD-ESR derived MEFs and BMK cells. In both cell
types we observed that, like in tissues, complete loss of SdhD led to
accumulation of this protein whereas no increase was observed in
heterozygous SdhD+/2 cells. Our observations unveil a new link
between the loss of the tumor suppressor gene SdhD and p21WAF1/
Cip1 activation that occurs in a general manner.
Regarding the biological consequences of this observation, it is
widely accepted, although not demonstrated, that after the loss of
the two copies of the SDHD gene has occurred, a third hit seems to
be required for the tumorigenic process to start [30]. This would
be a requirement specific for SDHD, as tumor development in
SDHB, SDHC and SDHA appear to follow a two-hit kinetics. To
date, the nature of this hypothetical third hit is completely
unknown. In the light of our results, and given the implication of
p21WAF1/Cip1 in the cell cycle, proliferation, and senescence, we
propose that the SdhD-mutation-induced p21WAF1/Cip1 up-regula-
tion could represent a checkpoint mechanism activated upon
MCII failure. Thus, any subsequent molecular event that causes
the cell division machinery to by-pass this checkpoint would drive
the cells to replicative catastrophe, accumulating mutations and
Table 4. Biological functions predicted to be affected in the SDHD-ESR kidney.
Functions
Annotation p-Value
Predicted
Activation
State
Activation
z-score
#
Genes Genes
cell movement
(migration of cells)
4,29E-03 Increased 3,227 52 ANGPTL3, B4GALT1, BMP4, BTC, C3, CALML3, CD8A, CDKN1A, CEBPD, Chi3l3/Chi3l4,
EPHB3, ERF, ESR1, FGA, FGB, FOSL2, HP, ID1, ID3, IL15RA, IL33, IL6R, IRS2, Klra4 (includes
others), LCN2, MAP3K5, MCAM, MST1R, MYC, NCOA4, NFKBIA, NQO1, OSMR, Pde4d,
PPARA, PRAP1, PRNP, PTPN1, PTPRJ, REST, RGS3, SCNN1A, SLC1A3, SLC37A4, SOCS2,
SOCS3, SPP1, STAT3, STIM1, TNFRSF21, TNFRSF9, XDH.
cell viability and
survival (apoptosis)
1,85E-04 Increased 3,020 42 ABCC3, ATF2, BMP4, BNIP3, BTC, CD8A, CDKN1A, CEBPD, CISH, ESR1, FA2H, FGF18,
FHIT, IL33, IL6R, IRS2, LCN2, MAP3K5, MCAM, MGST1, MMS22L, MYC, MYOD1, NFIL3,
NFKBIA, OGG1, PPP2R2B, PRNP, PTPN1, SLC1A3, SLC22A8, SLC37A4, SOCS2, SOCS3,
SPP1, STAT3, TNFRSF9, UNG, XDH, XPA.
differentiation of cells
(tubulation of
endothelial cells)
4,92E-04 Increased 2,886 56 ATF2, BGLAP, BMP4, BNIP3, BTC, BTG1, C3, CD8A, CDKN1A, CEBPD, CLCF1, CYTL1,
EPHB3, ERF, ESR1, EYA1, FGF18, FLVCR1, FOSL2, HSD11B1, ID1, ID3, IFRD1, IHH, IKZF4,
IL15RA, IL33, IL6R, IRS2, LCN2, MAFF, MAP3K5, MST1R, MYC, MYOD1, NFIL3, NFKBIA,
PPARA, PRNP, PTPN1, PTPRJ, REST, RPS3A, SCD, SLC1A3, SLC37A4, SMAD6, SMARCD3,
SOCS2, SOCS3, SPP1, STAT3, STIM1, TNFRSF9, TRIB3, XDH.
interphase 3,13E-03 Increased 2,641 23 ATF2, BMP4, BTG1, Camk2b, CDKN1A, CEBPD, ESR1, FHIT, ID1, ID3, IL6R, MAP3K5,
MMS22L, MYC, NFKBIA, PPARA, PRNP, SIAH1, SMAD6, STAT3, STK38L, XPA, ZBTB10.
transport of
carbohydrate
5,55E-04 Increased 2,467 10 ABCC3, B4GALT1, C3, IRS2, MGAT4A, PPP1R3B, SLC1A3, SLC37A4, SLC5A1, TRIB3.
oxidation of lipid
(beta-oxidation
of fatty acid)
7,60E-05 Increased 2,203 12 C3, CYP27A1, CYP4A11, HACL1, HSD11B1, IRS2, PNPLA2, PON1, PPARA, Rdh1 (includes
others), SAT1, SCD.
metabolism of
amino acids
4,71E-03 Increased 2,183 8 BHMT, DDC, GLDC, GLS, KYNU, MYC, PPARA, SLC1A3.
proliferation of cells
(generation of
lymphocytes;
cytostasis; proliferation
of mammary tumor
cells and neuroblasts)
5,99E-03 Increased 2,101 84 ABCC3, APOD, Art2a-ps/Art2b, ATF2, B4GALT1, BMP4, BNIP3, BTC, BTG1, C3, CACNA1G,
CBR1, CD8A, CDCA4, CDKN1A, CEBPD, CISH, CLCF1, CYP20A1, EPHA5, EPHB3, ERAL1,
ERF, ESR1, EYA1, FA2H, FGA, FGF18, FHIT, FOSL2, GP2, HSD11B1, HTR3A, ID1, ID3, IHH,
IL15RA, IL33, IL34, IL6R, IRS2, ITIH4, LCN2, MAFF, MAP3K5, MCAM, MST1R, MYC,
MYOD1, NCOA4, NFKBIA, NMB, NQO1, OSMR, PDXK, PPARA, PRNP, PTPN1, PTPRJ, REST,
RING1, RPS3A, SAT1, SF1, SIAH1, SLC1A3, SLC20A1, SMAD6, SMARCD3, SOCS2, SOCS3,
SPP1, STAT3, STIM1, STK38L, SULF2, TNFRSF21, TNFRSF9, TRIM25, TSC22D1, UTP20,
VPS53, XDH, XPA.
necrosis 3,03E-04 Increased 2,003 69 ALDH2, ALDH3B1, Art2a-ps/Art2b, ATF2, ATXN7, BMP4, BNIP3, BTC, BTG1, C3,CD8A,
CDKN1A, CEBPD, CISH, CLCF1, EHMT1, ESR1, FAM134B, FAM176C, FGA, FGF18, FHIT,
GP2, ID1, ID3, IFRD1, IL15RA, IL33, IL6R, IRS2, ITIH4, Klra4 (includes others), LCN2,
MAP3K5, MMS22L, MST1R, MYC, MYOD1, NFIL3, NFKBIA, NQO1, OGFOD1, PNPLA2,
PPARA, PPP2R2B, PRNP, PTPN1, REST, RGS3, RPS3A, SAT1, SCD, SEMA7A, SGCG, SIAH1,
SLC1A3, SLC20A1, SMAD6, SOCS3, SPP1, STAT3, STIM1, TNFRSF21, TNFRSF9, TRIB3,
TSC22D1, UNG, XDH, XPA.
concentration of
triacylglycerol
2,35E-08 Decreased 22,520 21 ANGPTL3, APOD, BGLAP, BHMT, C3, CIDEC, CYP27A1, HSD11B1, IFRD1, IRS2, MGAT4A,
MYC, NQO1, PNPLA2, PON1, PPARA, PTPN1, SCD, SLC37A4, SPP1, XDH.
binding of DNA 7,09E-07 Decreased 22,635 28 ATF2, BTAF1, CDKN1A, CEBPD, CISH, ERF, ESR1, FOSL2, HIF3A, HP, ID1, ID3, IL33, IL6R,
MYC, MYOD1, NFKBIA, PPARA, PTPN1, REST, SCD, SOCS2, SOCS3, SPP1, STAT3, TRIB3,
XPA, ZBTB10.
doi:10.1371/journal.pone.0085528.t004
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eventually resulting in tumor transformation. Our findings,
therefore, open new avenues for the identification of candidate
genes involved in the cell cycle and growth, genome integrity, and
other processes, whose mutations could result in the oncogenic
transformation of Sdh-deficient tissues.
Previous reports in humans, based on gene expression profiling
and unsupervised hierarchical clustering, demonstrate a tight
association between pheochromocytomas with VHL and SDH
mutations, which distinguishes them from pheochromocytomas
with MEN2, RET, and NF1 mutations [10,38,39]. Among the
genes determining these clustering phenomena, the p21 encoding
Cdkn1a gene was found in the study by Dahia et al [10], whereas
the closely related Cdkn1c, encoding the cyclin-dependent kinase
inhibitor 1C (p57, Kip2), was found differentially expressed in a
study by Lopez-Jimenez et al [39]. In addition, in a work by Merlo
et al [40] where paraganglioma tissue was compared with normal
paraganglia, Cdkn1a was present among a total of 1296 differen-
tially expressed genes. Together, these data support a role of p21
in Sdh-related tumorigenesis in humans.
The fact that a third hit event does not take place in our SDHD-
ESR mouse model could be attributable to many circumstances. It
could be that the shorter life-span resulting from administration of
the minimal effective dose of tamoxifen, i. e., the minimal amount
tested to cause reliable deletion of the SdhD gene, does not allow
subsequent tumorigenic events to occur. Nevertheless, a tissue-
specific mutant with a longer life-span than that of the SDHD-
ESR model does not show any tendency to form tumors [27].
Therefore, other genetic factors, such as gene redundancy,
different chromosomal arrangement, or different susceptibility to
the lack of one SdhD allele (i.e. haploinsufficiency), could account
for these differences between humans and mice.
An alternative role for p21WAF1/Cip1 as an onco-protein in Sdh-
deficient tissues could also be discussed. Although the well
described role of p21WAF1/Cip1 as a tumor suppressor opposes a
mechanism in which its induction is associated with tumorigenesis
[36,37], it has been demonstrated that under certain conditions,
p21WAF1/Cip1 can promote cellular proliferation and oncogenicity
[36,41]. Indeed, its overexpression or cytoplasmic localization
correlates with poor prognosis in certain malignant tumors ([37]
and references therein).
The transcriptional activation of the Cdkn1a gene seems to be
independent of p53 at least in the SDHD-ESR derived MEFs and
BMK cells, as these cells were immortalized by stable expression of
a p53-dominant negative protein (see methods section) or SV40
large T antigen, which eventually also inactivates p53. Although
we do not rule out that in mouse tissues p53 plays a role in SdhD-
mutation-induced p21WAF1/Cip1 induction, such p53-independent
expression of p21WAF1/Cip1 has been reported in other situations
[42]. It is also worth noting a study by Young et al., in which acute
inactivation of pVHL –the ubiquitin ligase part of the proteasome
that downregulates Hif1a under normoxic conditions- caused a
senescent-like phenotype in MEFs, with overexpression of p27,
another cyclin-kinase inhibitor. This phenotype is independent of
p53 and Hif1a, even though Hif1a and Glut1 proteins were
accumulated in these cells [43].
Complete loss of SdhD induces overexpression of the glucose
transporter, Glut1, in our cultured cells, which indicates a
metabolic switch towards glycolysis. This change in gene
expression seems to be mediated by a ‘‘pseudo-hypoxic’’ response
in which Hif1a plays a central regulatory role [11,12,13].
However, it is conceivable that, even though the up-regulation
of Glut1 may be caused in the first instance by activated Hif1a, the
complete loss of mitochondrial function will eventually force the
cells to undergo a glycolytic switch with gene expression changes
independent of Hif1a. Indeed, a general and rapid Hif-mediated
‘‘pseudo-hypoxic’’ response cannot be addressed from the SDHD-
ESR model, as some bona fide Hif-target genes are not affected in a
general and consistent manner (Table 1). Our cell culture
experiments also showed that Hif1a stabilization is transient,
which possibly makes difficult to detect this protein in SDHD-ESR
Figure 6. Analysis of p21WAF/Cip in SDHD-ESR-derived cell lines. A, B. Western blot of p21WAF1/Cip1 in total protein extracts of (A) MEFs and
(B) BMK cells obtained from SDHD-ESR mice and their homozygous SdhDflox/+ (+/+) and heterozygous SdhDflox/2 (+/2) littermates and cultured in
medium supplemented with 4-hydroxy-tamoxifen for 4 or 24 hours. Quantification of relative p21WAF1/Cip1 band intensities in (C) MEFs and (D) BMK
cells normalized to b-actin signal. Results are the average 6 SEM of three independent experiments. Two different immortalized clones were
generated for each genotype and cell type giving the same results. *, P#0.05; ***, P#0.001; for 0 hours, i.e. in the absence of 4-hydroxy tamoxifen,
versus 4 or 24 hours of incubation in 4-hydroxytamoxifen.
doi:10.1371/journal.pone.0085528.g006
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tissues after tamoxifen administration. In this regard, it has been
demonstrated that reactivation of PHDs takes place upon
sustained hypoxia [44]. Although the same could happen in
response to SdhD deficiency, a marginal contribution of Hif1a to
the observed phenotypes cannot be ruled out. Indeed, the
microarray analysis of SDHD-ESR tissues did not show a general
gene expression profile responsive to hypoxia. Finally, it is
noteworthy that we also did not observe any evidence of
‘‘pseudo-hypoxia’’- driven changes in gene expression in either
partially SdhD-deficient heterozygous tissues or in derivative cells
with the same phenotype. Taken together, our data suggest that a
pathogenic role for SdhD-mutation-induced Hif1a accumulation
cannot be definitively established. Instead, it could play an
important role in tumor progression once it has already been
formed.
One striking issue regarding tumors caused by mutations in
MCII or associated proteins concerns tissue specificity. Although
in recent years this has been partially resolved by the fact that Sdh-
mutation-related tumors are found in other organs, there is a
preferential trend for these types of tumor to arise in paragangli-
onic system-derived tissues. It has been proposed that an intrinsic
ability of these organs to detect oxygen might underlie a
predisposition to form tumors [30]. However, other biological
characteristics could be equally relevant. Thus, the difference in
gene expression changes between the adrenal medulla and kidney
found in our study indicates that these tissues respond differently to
SdhD deletion. In the adrenal medulla, a response pointing towards
inhibition of the inflammatory response and immune surveillance
is elicited, with changes in the expression of many chemokines,
cytokines, and their receptors. The kidney, however, responds in a
more ‘‘predictable’’ manner, with many metabolic readjustments
promoting cell viability and survival. The physiological relevance
of these changes will be explored in future work.
Conclusions
The identification of p21WAF1/Cip1 as one molecule that responds
in a general manner to complete SdhD deletion, together with its
critical role in the cell cycle, senescence, and DNA integrity, paints a
new picture of the molecular and cellular responses that take place
after MCII dysfunction. The precise mechanism that signals
mitochondrial dysfunction to p21WAF1/Cip1 activation as well as its
cellular effects will be explored in future work. Additionally, a more
exhaustive analysis of the large dataset of affected genes generated in
this study, and the pathways in which they are involved, will open
new avenues towards identifying other processes that could
contribute to tumorigenesis and, ideally, will help to identify
molecular targets for the treatment of these types of tumors.
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